Cyclopharm Limited (ASX:CYC) insider Thomas (Tom) McDonald acquired 13,800 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was acquired at an average cost of A$1.46 ($1.04) per share, with a total value of A$20,189.40 ($14,318.72).
Thomas (Tom) McDonald also recently made the following trade(s):
- On Thursday, June 27th, Thomas (Tom) McDonald purchased 1,170 shares of Cyclopharm stock. The shares were purchased at an average cost of A$1.47 ($1.05) per share, with a total value of A$1,724.58 ($1,223.11).
Shares of CYC stock remained flat at $A$1.49 ($1.05) during mid-day trading on Friday. Cyclopharm Limited has a 52-week low of A$0.85 ($0.60) and a 52-week high of A$1.51 ($1.07). The firm has a fifty day simple moving average of A$1.45. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.33 and a current ratio of 2.96. The firm has a market cap of $102.02 million and a price-to-earnings ratio of -1,485.00.
Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The company offers diagnostic equipment and consumables, which are used by physicians in the detection of pulmonary embolism.
Recommended Story: How is a management fee different from a performance fee?
Receive News & Ratings for Cyclopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclopharm and related companies with MarketBeat.com's FREE daily email newsletter.